Location:Room 14b (ICM, Level 1)
PSA relapse after curative treatment is always a troublesome situation for patients and doctors. Usually, patients have recovered well from surgery or radiotherapy and most of them may be potent and continent. Therefore, in terms of quality of life androgen deprivation treatment (ADT) is not really first choice. Deferred radiotherapy to the prostate field will miss lymph node metastasis. There is no clear pattern of relapse or clinical scenario that would predict the location of recurrence. Imaging tools are urgently needed for early detection of relapse in order to tailor treatment. Local treatment by lymph node dissection or radiotherapy may prevent early need for ADT. However, PET images suffer from low sensitivity to detect lesions below 5 mm. New PSMA data suggest an improvement of the specificity but large series of histological confirmation are missing. This session will summarise the current standard of care in the PET diagnosis of PSA-detected PCA relapse. In addition, possible treatment strategies using PSMA radionuclide conjugates will be discussed. Further, data concerning MRI versus CT imaging will be presented.
The objective of this presentation is to provide a current overview of PSMA PET-based hybrid imaging in recurrent prostate cancer. The value of PET/CT and PET/MR for detection as well as comparison to other PET tracers will be discussed. Future possible indications and limitations will be mentioned.
The recent advances in PET imaging lead to the management of patients with minimal recurrence of prostate cancer after curative treatment. Despite the lack of strong evidence regarding the treatment fo such recurrences, to date the results of these imaging modalities cannot be ignored. Recently, surgical and radiotherapic approaches have been described for the treatment of these recurrences. The aim of the presentation is to review the available results of these new treatment modalities.